Veena Viswanath

This inventor holds 54 USPTO granted patents and 13 published patent applications, plus 12 CIPO patents and 19 EPO patents, primarily in Chemokine Receptor Modulators (CPC class C07D). Top assignee: Allergan, Inc.. Active years: 2013-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Veena Viswanath. Retrieved from https://idiyas.com/inventor/veena-viswanath

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 54 (Patent Applications = 13)

% Patents Active = 92.6

CIPO Patents = 12 (Patent Applications = 4)

EPO Patents = 19 (Patent Applications = 31)

Average Co-Inventor Count = 5.1

ph-index = 6

Forward Citations = 155(Granted Patents)

Forward Citations (Not Self Cited) = 34(Dec 10, 2025)

Inventors with similar research interests:

Company Filing History:

54 out of 2,287

Allergan, Inc.

patents

Years Active: 2013-2021

Loading Chart...

Areas of Expertise:

Chemokine Receptor Modulators

Formyl Peptide Receptor Agonists

D-Serine Transporter Inhibitors

Sulfur Derivatives

Aromatic Bycyclic Derivatives

Amide Derivatives

Carbamoyl Hydrazine Derivatives

Benzofuran Derivatives

N-Urea Substituted Amino Acids

Regulatory T Cells

Ocular Inflammatory Diseases

Dermatological Diseases

54 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11208377 - 3,4-disubstituted 3-cyclobutene-1,2-diones and use thereof (2021-12-28),

2. 11046644 - Sulfur derivatives as chemokine receptor modulators (2021-06-29),

3. 10993931 - Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators (2021-05-04),

4. 10899780 - Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases (2021-01-26),

5. 10799518 - Use of agonists of formyl peptide receptor 2 for treating dermatological diseases (2020-10-13),

6. 10434112 - Use of agonists of formyl peptide receptor 2 for treating dermatological diseases (2019-10-08),

7. 10287243 - Sulfur derivatives as chemokine receptor modulators (2019-05-14),

8. 10251865 - Method of activating regulatory T cells with alpha-2B adrenergic receptor agonists (2019-04-09),

9. 10208071 - Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases (2019-02-19),

10. 10172832 - Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators (2019-01-08),

11. 9974772 - Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators (2018-05-22),

12. 9868700 - Carbamoyl hydrazine derivatives as formyl peptide modulators (2018-01-16),

13. 9850264 - Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases (2017-12-26),

14. 9670190 - Pyridinyl and pyrimidinyl sulfonamide derivatives as chemokine receptor modulators (2017-06-06),

15. 9670150 - (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators (2017-06-06),

Title: A Spotlight on Veena Viswanath: Innovator in Pharmaceutical Patents

Introduction

Veena Viswanath, based in Irvine, California, is an accomplished inventor whose innovative contributions to pharmaceuticals have resulted in an impressive portfolio of 54 patents. His work has been instrumental in developing compounds that address critical health issues, particularly inflammatory and autoimmune diseases.

Latest Patents

One of Veena's significant recent patents includes a formulation of 3,4-disubstituted 3-cyclobutene-1,2-diones. This invention describes novel compounds or pharmaceutically acceptable salts that are useful in the treatment of inflammatory and autoimmune conditions. Additionally, he has pioneered a patent relating to sulfur derivatives as chemokine receptor modulators. This invention outlines new sulfur compounds, their preparation processes, and their utilization in pharmaceutical compositions designed to modulate chemokine receptors.

Career Highlights

Throughout his career, Veena has been associated with major firms in the pharmaceutical industry, including Allergan, Inc. and Allegran, Inc. His tenure at these companies has not only honed his expertise in drug development but also strengthened his role as a leading inventor in the field.

Collaborations

In his professional journey, Veena has collaborated with notable colleagues, including John E. Donello and Richard L. Beard. These collaborations have likely enriched the innovation process leading to the development of his patents, fostering an environment of shared expertise and knowledge.

Conclusion

Veena Viswanath's dedication to innovation in the pharmaceutical industry is evident through his numerous patents and collaborative efforts. His work continues to influence the treatment landscape for various diseases, showcasing the vital role inventors play in advancing healthcare solutions. Through his inventions, Veena not only contributes to scientific knowledge but also aims to improve patient outcomes globally.

Profile summary based on public USPTO records.